Sugi Predict

Sugi Predict / Targets / KDM5D

KDM5D

Lysine-specific demethylase 5D · Q9BY66 · KDM5D on Sugi Atlas →

502 patent compounds predicted against KDM5D, 334 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL25380189 SCHEMBL25380189 1.00 1/20
SCHEMBL29549478 SCHEMBL29549478 1.00 1/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL31236648) 0.98 1/20
SCHEMBL15636679 SCHEMBL15636679 0.81 1/20
SCHEMBL15637682 SCHEMBL15637682 0.78 1/20
SCHEMBL15637431 SCHEMBL15637431 0.77 1/20
SCHEMBL29373338 SCHEMBL29373338 0.77 1/20
SCHEMBL18286849 SCHEMBL18286849 0.75 1/20
SCHEMBL16293178 SCHEMBL16293178 0.74 1/20
SCHEMBL17364565 SCHEMBL17364565 0.73 1/20
SCHEMBL15636176 SCHEMBL15636176 0.72 1/20
SCHEMBL19676470 SCHEMBL19676470 0.72 1/20
SCHEMBL15994347 SCHEMBL15994347 0.72 1/20
SCHEMBL15637608 SCHEMBL15637608 0.71 1/20
SCHEMBL15994214 SCHEMBL15994214 0.71 1/20
SCHEMBL18880308 SCHEMBL18880308 0.71 1/20
SCHEMBL16291430 SCHEMBL16291430 0.70 1/20
SCHEMBL18708524 SCHEMBL18708524 0.70 1/20
SCHEMBL26862785 SCHEMBL26862785 0.69 1/20
SCHEMBL15635919 SCHEMBL15635919 0.68 1/20

Clinical trials — most relevant to KDM5D by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC PHASE3UNKNOWN
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma PHASE2SUSPENDED
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2 PHASE2ACTIVE_NOT_RECRUITING
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma PHASE1RECRUITING
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors PHASE1RECRUITING
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
Lysine-specific Demethylase 1 and Salt-sensitivity in Humans nanACTIVE_NOT_RECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
The Danish TURNER Cryopreservation Study nanRECRUITING
The Crosstalk Between the Epigenome and Mitochondria in SCI nanNOT_YET_RECRUITING
Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19 nanCOMPLETED
Expression of TET1 Gene in Acute Leukaemia nanUNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy nanRECRUITING
The Molecular Pathogenesis Study of Cataract nanUNKNOWN
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders nanCOMPLETED
Mechanisms of Immune Deficiency nanUNKNOWN
Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia nanUNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing nanRECRUITING
Model to Predict pCR and IrAEs in Early Stage Non-small Cell Lung Cancer nanUNKNOWN
Epitranscriptomic Blood Biomarkers for Coronary Artery Disease - A Prospective Cohort Study (IHD-EPITRAN) nanUNKNOWN
Screening of IDH1 and IDH2 Gene Mutations in Adult Acute Myeloid Leukemia for Possible Targeted Therapy nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a KDM5D binder may also engage these)

ProteinNameSimilarity
Q5XUN4 — 1.000 Q5XUN4 →
P41230 — 1.000 P41230 →
Q30DN6 — 1.000 Q30DN6 →
Q80Y84 — 1.000 Q80Y84 →
Q6IQX0 — 1.000 Q6IQX0 →
Q3UXZ9 — 1.000 Q3UXZ9 →
KDM5B Lysine-specific demethylase 5B 1.000 landscape →
Q62240 — 1.000 Q62240 →
Q61T02 — 1.000 Q61T02 →
KAT8 Histone acetyltransferase KAT8 1.000 landscape →
KDM5A Lysine-specific demethylase 5A 1.000 landscape →
Q5F3R2 — 0.999 Q5F3R2 →
A1YVX4 — 0.998 A1YVX4 →
Q9VMJ7 — 0.997 Q9VMJ7 →
Q9H1H9 — 0.997 Q9H1H9 →
P25799 — 0.997 P25799 →
Q7Z3E5 — 0.996 Q7Z3E5 →
A3KMI0 — 0.996 A3KMI0 →
KDM4B Lysine-specific demethylase 4B 0.996 landscape →
INPP5B Type II inositol 1,4,5-trisphosphate 5-phosphatase 0.996 landscape →
Q6GM53 — 0.996 Q6GM53 →
Q6P158 — 0.996 Q6P158 →
NFKB1 Nuclear factor NF-kappa-B p105 subunit 0.995 landscape →
C3XRY1 — 0.995 C3XRY1 →
B5E0H4 — 0.995 B5E0H4 →
Q9W3D3 — 0.995 Q9W3D3 →
Q6GM71 — 0.995 Q6GM71 →
Q8BMD7 — 0.995 Q8BMD7 →
Q6C710 — 0.995 Q6C710 →
C0SUU8 — 0.995 C0SUU8 →